Cargando…
Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice
Diabetes mellitus (DM) is one of the major causes of death in the world. There are two types of DM—type 1 DM and type 2 DM. Type 1 DM can only be treated by insulin injection whereas type 2 DM is commonly treated using anti-hyperglycemic agents. Despite its effectiveness in controlling blood glucose...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582334/ https://www.ncbi.nlm.nih.gov/pubmed/32987643 http://dx.doi.org/10.3390/molecules25194381 |
_version_ | 1783599167293095936 |
---|---|
author | Faizah, Zakiyatul Amanda, Bella Ashari, Faisal Yusuf Triastuti, Efta Oxtoby, Rebecca Rahaju, Anny Setijo Aziz, M. Aminudin Lusida, Maria Inge Oceandy, Delvac |
author_facet | Faizah, Zakiyatul Amanda, Bella Ashari, Faisal Yusuf Triastuti, Efta Oxtoby, Rebecca Rahaju, Anny Setijo Aziz, M. Aminudin Lusida, Maria Inge Oceandy, Delvac |
author_sort | Faizah, Zakiyatul |
collection | PubMed |
description | Diabetes mellitus (DM) is one of the major causes of death in the world. There are two types of DM—type 1 DM and type 2 DM. Type 1 DM can only be treated by insulin injection whereas type 2 DM is commonly treated using anti-hyperglycemic agents. Despite its effectiveness in controlling blood glucose level, this therapeutic approach is not able to reduce the decline in the number of functional pancreatic β cells. MST1 is a strong pro-apoptotic kinase that is expressed in pancreatic β cells. It induces β cell death and impairs insulin secretion. Recently, a potent and specific inhibitor for MST1, called XMU-MP-1, was identified and characterized. We hypothesized that treatment with XMU-MP-1 would produce beneficial effects by improving the survival and function of the pancreatic β cells. We used INS-1 cells and STZ-induced diabetic mice as in vitro and in vivo models to test the effect of XMU-MP-1 treatment. We found that XMU-MP-1 inhibited MST1/2 activity in INS-1 cells. Moreover, treatment with XMU-MP-1 produced a beneficial effect in improving glucose tolerance in the STZ-induced diabetic mouse model. Histological analysis indicated that XMU-MP-1 increased the number of pancreatic β cells and enhanced Langerhans islet area in the severe diabetic mice. Overall, this study showed that MST1 could become a promising therapeutic target for diabetes mellitus. |
format | Online Article Text |
id | pubmed-7582334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75823342020-10-28 Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice Faizah, Zakiyatul Amanda, Bella Ashari, Faisal Yusuf Triastuti, Efta Oxtoby, Rebecca Rahaju, Anny Setijo Aziz, M. Aminudin Lusida, Maria Inge Oceandy, Delvac Molecules Article Diabetes mellitus (DM) is one of the major causes of death in the world. There are two types of DM—type 1 DM and type 2 DM. Type 1 DM can only be treated by insulin injection whereas type 2 DM is commonly treated using anti-hyperglycemic agents. Despite its effectiveness in controlling blood glucose level, this therapeutic approach is not able to reduce the decline in the number of functional pancreatic β cells. MST1 is a strong pro-apoptotic kinase that is expressed in pancreatic β cells. It induces β cell death and impairs insulin secretion. Recently, a potent and specific inhibitor for MST1, called XMU-MP-1, was identified and characterized. We hypothesized that treatment with XMU-MP-1 would produce beneficial effects by improving the survival and function of the pancreatic β cells. We used INS-1 cells and STZ-induced diabetic mice as in vitro and in vivo models to test the effect of XMU-MP-1 treatment. We found that XMU-MP-1 inhibited MST1/2 activity in INS-1 cells. Moreover, treatment with XMU-MP-1 produced a beneficial effect in improving glucose tolerance in the STZ-induced diabetic mouse model. Histological analysis indicated that XMU-MP-1 increased the number of pancreatic β cells and enhanced Langerhans islet area in the severe diabetic mice. Overall, this study showed that MST1 could become a promising therapeutic target for diabetes mellitus. MDPI 2020-09-24 /pmc/articles/PMC7582334/ /pubmed/32987643 http://dx.doi.org/10.3390/molecules25194381 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Faizah, Zakiyatul Amanda, Bella Ashari, Faisal Yusuf Triastuti, Efta Oxtoby, Rebecca Rahaju, Anny Setijo Aziz, M. Aminudin Lusida, Maria Inge Oceandy, Delvac Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice |
title | Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice |
title_full | Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice |
title_fullStr | Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice |
title_full_unstemmed | Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice |
title_short | Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice |
title_sort | treatment with mammalian ste-20-like kinase 1/2 (mst1/2) inhibitor xmu-mp-1 improves glucose tolerance in streptozotocin-induced diabetes mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582334/ https://www.ncbi.nlm.nih.gov/pubmed/32987643 http://dx.doi.org/10.3390/molecules25194381 |
work_keys_str_mv | AT faizahzakiyatul treatmentwithmammalianste20likekinase12mst12inhibitorxmump1improvesglucosetoleranceinstreptozotocininduceddiabetesmice AT amandabella treatmentwithmammalianste20likekinase12mst12inhibitorxmump1improvesglucosetoleranceinstreptozotocininduceddiabetesmice AT asharifaisalyusuf treatmentwithmammalianste20likekinase12mst12inhibitorxmump1improvesglucosetoleranceinstreptozotocininduceddiabetesmice AT triastutiefta treatmentwithmammalianste20likekinase12mst12inhibitorxmump1improvesglucosetoleranceinstreptozotocininduceddiabetesmice AT oxtobyrebecca treatmentwithmammalianste20likekinase12mst12inhibitorxmump1improvesglucosetoleranceinstreptozotocininduceddiabetesmice AT rahajuannysetijo treatmentwithmammalianste20likekinase12mst12inhibitorxmump1improvesglucosetoleranceinstreptozotocininduceddiabetesmice AT azizmaminudin treatmentwithmammalianste20likekinase12mst12inhibitorxmump1improvesglucosetoleranceinstreptozotocininduceddiabetesmice AT lusidamariainge treatmentwithmammalianste20likekinase12mst12inhibitorxmump1improvesglucosetoleranceinstreptozotocininduceddiabetesmice AT oceandydelvac treatmentwithmammalianste20likekinase12mst12inhibitorxmump1improvesglucosetoleranceinstreptozotocininduceddiabetesmice |